Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
Our findings establish a connection between type I interferon signalling, pyrimidine metabolism and uremic toxins in patients with LN and support the evaluation of urine uracil as a potential biomarker of response to anifrolumab.
Authors
- Eduardo Mysler (ORCID: https://orcid.org/0000-0002-8993-0313)
- Hussein Al‐Mossawi (ORCID: https://orcid.org/0000-0002-2312-3754)
- Catharina Lindholm
- Patrick G. Gavin (ORCID: https://orcid.org/0000-0003-0325-7082)
- Eszter Csomor (ORCID: https://orcid.org/0000-0001-8195-2481)
- Helen Stone (ORCID: https://orcid.org/0000-0002-3344-5079)
- Daniel Muthas (ORCID: https://orcid.org/0000-0001-9320-2004)
- Philip Z. Brohawn (ORCID: https://orcid.org/0000-0002-7413-6539)
- Erik L. Allman (ORCID: https://orcid.org/0000-0002-6560-0889)
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Sonja Y. Hess (ORCID: https://orcid.org/0000-0002-5904-9816)
- Cristina Di Poto
- Nicola Ferrari
- Adam Platt (ORCID: https://orcid.org/0000-0002-3455-1789)
- Kevin Woollard (ORCID: https://orcid.org/0000-0002-9839-5463)
- Xiang Tian (ORCID: https://orcid.org/0000-0002-4616-0304)
- Asha Seth (ORCID: https://orcid.org/0000-0003-0813-4620)
- Zahir Amoura
- Consuelo Anzillotti
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Cambridge (GB)
- Sorbonne Université (FR)
- AstraZeneca (South Korea) (KR)
- Pitié-Salpêtrière Hospital (FR)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-005932
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca